Need Help?
Copied to clipboard!

Multi-omic signatures in multiple myeloma

Multiple myeloma (MM) is a genetically and clinically heterogeneous plasma-cell malignancy. Quadruplet therapy, combining anti-CD38 antibodies, immunomodulatory drugs, proteasome inhibitors, and dexamethasone, is now the standard induction treatment for newly diagnosed multiple myeloma (NDMM). To gain a comprehensive view of molecular changes in MM and their association with treatment response in this new standard care, we performed a multi-omic study of 423 NDMM from the MIDAS trial.

Cite

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000002250 Illumina NovaSeq X 204
EGAD50000002251 Illumina NovaSeq X 44
EGAD50000002252 Illumina NovaSeq X 120
EGAD50000002482 Illumina NovaSeq X 214
EGAD50000002483 Illumina NovaSeq X 250
EGAD50000002687 207
EGAD50000002688 Illumina NovaSeq X 55
EGAD50000002807 Illumina NovaSeq X 189